Desidustat (ZYAN1) is a novel HIF prolyl hydroxylase (PHD) inhibitor under clinical development for the treatment of anemia.
Desidustat (ZYAN1) increases circulating EPO levels after acute treatment in mice (10.3±3.7 and 40.0±8.5 fold rise at 15 and 30 mg/kg, respectively).
Desidustat (ZYAN1) demonstrates hematinic potential by combined effects on EPO release and efficient iron utilization in nephrectomized rats.
